Clinical trials: Insulin Resistance, Diabetes
- Condition Insulin Resistance, Diabetes
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 1 Diabetes
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Primary objective To determine whether oral ladarixin versus placebo adjunctive therapy improves glycemic control in overweight, insulin resistant (IR) adult subjects with type 1 diabetes (T1D).
- Trial name
- CONSERVA (NCT05368402)
- Testing
- Ladarixin
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 in combination with Metformin in patients with type 2 diabetes for 24 weeks administration and to evaluate the safety and efficacy of MP-513 in…
- Trial name
- NCT00971243
- Testing
- MP-513 Lowest Dose and Metformin, MP-513 Low Dose and Metformin, MP-513 Medium Dose and Metformin
- Where
- 44 sites in Denmark, Germany and 5 more
- Volunteers
- 448 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 1
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other…
- Trial name
- NCT00883558
- Testing
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of…
- Trial name
- NCT00974090
- Testing
- Teneli / Teneli + SU
- Where
- Japan
- Volunteers
- 194 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus
- Trial name
- DERISC (NCT02426541)
- Testing
- Dapagliflozin
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes
Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality.
- Trial name
- NCT00509223
- Testing
- Positive Airway Pressure therapy, Lifestyle counseling
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- ResMed
Diabetes Type 2
A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial
Type 2 diabetes is being acknowledged as a potential public health time bomb, whose incidence is predicted to double over the next 10 years in the UK, associated with the rise in obesity and increasing sedentary lifestyles.
- Trial name
- NCT01617603
- Testing
- Cocoa Polyphenols
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- Société des Produits Nestlé (SPN)
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration.
- Trial name
- NCT02220920
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 146 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes…
- Trial name
- NCT02104804
- Testing
- Saxagliptin 5mg
- Where
- 11 sites in China
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs).
- Trial name
- NCT00348374
- Testing
- Insulin Lispro, Exubera
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 191 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
- Trial name
- NCT00998881
- Testing
- Teneligliptin 20 mg
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
- Trial name
- NCT00831779
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER1 (NCT03371082)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 85 sites in United States, Czechia and 4 more
- Volunteers
- 576 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Type 2 Diabetes
Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and…
- Trial name
- NCT00628212
- Testing
- Teneligliptin 10mg, Teneligliptin 20 mg, Teneligliptin 40 mg
- Where
- Japan
- Volunteers
- 324 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
- Trial name
- MOSAIc (NCT01400971)
- Where
- 153 sites in United States, Argentina and 17 more
- Volunteers
- 4,299 people
- Sponsor
- Eli Lilly and Company
Obesity
Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), combined with a lifestyle modification program, compared to a sham control and a lifestyle modification…
- Trial name
- VeSTAL (NCT03640286)
- Testing
- VeSTAL
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus.
- Trial name
- NCT02622113
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Tanabe Pharma Corporation